Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | HTR1A | P08908 | 2/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | CDK4 | P11802 | 5/20 | 0.41 |
| ▸ | CCND1 | P24385 | 5/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7311382 | 0.86 | TRPV1 (0.47) | HTR1AADRA1DADRA1AADRA1BTRPV1 | |
| SCHEMBL8542630 | 0.79 | LMNA (0.62) | LMNAGRIN2B | |
| SCHEMBL8543754 | 0.78 | LMNA (0.64) | LMNA | |
| SCHEMBL7305217 | 0.77 | LMNA (0.72) | LMNA | |
| SCHEMBL7299161 | 0.76 | LMNA (0.71) | LMNA | |
| SCHEMBL7302805 | 0.76 | LMNA (0.71) | LMNAHTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL8544144 | 0.74 | LMNA (0.53) | LMNA | |
| SCHEMBL7304698 | 0.73 | LMNA (0.47) | LMNA | |
| SCHEMBL8546477 | 0.71 | LMNA (0.51) | LMNADRD2SIGMAR1 | |
| SCHEMBL7299169 | 0.68 | LMNA (0.58) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0666260-B1 | 3-(2-aminoethyl)-4-3-(trifluoromethyl)benzoyl-3,4-dihydro-2H-1,4-benzoxazine derivatives, their preparation and use in therapy | SYNTHELABO (FR) | 1999-08-04 | — | — | EP | disclosed |
| US-5550125-A | BRAIN DISORDERS | SYNTHELABO (FR) | 1996-08-27 | — | — | US | disclosed |
| EP-0666260-A1 | 3-(2-aminoethyl)-4-3-(trifluoromethyl)benzoyl-3,4-dihydro-2H-1,4-benzoxazine derivatives, their preparation and use in therapy | SYNTHELABO (FR) | 1995-08-09 | — | — | EP | disclosed |